How to provide the needed protection from COVID-19 to patients with hematologic malignancies

Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon review of 24 series there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.